The funding will support up to 90 percent of development costs for the Klaris system, which purportedly performs phenotypic testing in four hours.
The company raised $7.4 million in an extended Series B financing round and entered a partnership with BARDA valued at $7.6 million.
The clearance by the Chinese NMPA means the instrument can be used as a clinical diagnostic tool in hospitals, laboratories, and clinics in China.
The Canadian regulator gave Medical Device License approval to Beckman Coulter's DxH 900 Hematology Analyzer and its Early Sepsis Indicator.
The assay will combine the company's CytoSort assay with its automated AIR system for imaging, sorting, and isolating single cells and small colonies.
Martin Edelman will investigate whether cancer associated macrophage-like cells can determine whether small or indeterminate lung nodules are cancerous or benign.
The financing will go toward further development of Klaris' phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics.
Amid reporting a loss of about $2.0 million for the quarter, Celcuity also said that it had completed the development of its second test, for breast cancer, based on the CELx platform.
The firm's CEO said that by the end of the year, Celcuity will complete development of new cell-signaling function tests for breast and two other cancer types.
The cancer diagnostics company went public today on the Nasdaq with an initial public offering of 2.4 million shares, priced at $9.50 per share.